AI assistant
Mersana Therapeutics, Inc. — Director's Dealing 2017
Dec 21, 2017
34702_dirs_2017-12-21_545084cf-50ed-4472-bb30-150cffad089d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Mersana Therapeutics, Inc. (MRSN)
CIK: 0001442836
Period of Report: 2017-12-20
Reporting Person: Protopapas Anna (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-20 | Common Stock | M | 10417 | $1.53 | Acquired | 130719 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-20 | Option to Purchase Common Stock | $1.53 | M | 10417 | Disposed | 2025-05-07 | Common Stock (10417) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 72263 | Indirect |
Footnotes
F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2: The original option grant for 879,085 option shares vested 25% on March 2, 2016 and in quarterly installments thereafter.